What is the Ulcerative Colitis?

 

What is Ulcerative Colitis?

The term Inflammatory Bowel Disease (IBD) describes a group of disorders in which the intestines become inflamed. Two major types of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD). UC is limited to the colon or large intestine. CD, on the other hand, can involve any part of the gastrointestinal tract from the mouth to the anus. Approximately 10% of cases of IBD exhibit the features of both CD and UC. These are typically known as Indeterminate Colitis (IC).

UC is an inflammatory bowel idiopathic condition, whose exact cause still remains unknown. It affects the colonic mucosa and is characterized clinically by diarrhea, stomach discomfort, pain, and hematochezia. The extent of the disease is variable and may include either the rectum (ulcerative proctitis), the splenic flexure of the left side of the colon, or the whole of the rectum and bowel.

What are the Ulcerative Colitis Symptoms?

Symptoms of UC can range from mild to extreme and vary from individual to individual. Usually, patients have attacks of varying severity and length of bloody diarrhea, interspersed with asymptomatic intervals. Other commonly observed symptoms are Cramping in the abdominal, Tiredness and weakness, feeling unwell generally, Loss of appetite and weight loss and Anemia.

Also, Read @ Ulcerative Colitis Market

What is Ulcerative Colitis Diagnosis?

UC diagnosis is based on medical history and clinical judgment, laboratory, radiologic, endoscopic, histologic, and subsequently authenticated serological observations and findings. UC patients may be identified by degree of disease, severity of disease, age of onset, extraintestinal symptoms, and genetic markers.

What is Ulcerative Colitis Treatment?

Treatment for UC is complex and comprises the use of medication, alterations in diet and nutrition, and at times surgical procedures to repair or remove affected portions of patient’s GI tract. Currently there are several type of medications used for the treatment purpose, namely Aminosalicylates, Corticosteroids, Immunomodulators, Biologic therapies and Janus kinase (JAK) inhibitors. At times, combination therapy and dietary supplementation is also prescribed.

In the treatment of UC, the primary purpose is to help patients properly to control their immune system. A variety of treatment options may help the patient remain in control of the condition and lead a complete and rewarding life, but there is no proven cure for UC and flare ups may recur. A combination of treatment options can help the patient to stay in control of their disease and lead a fulfilling life. Treatment for UC is complex and comprises the use of medication, alterations in diet and nutrition, and at times surgical procedures to repair or remove affected portions of patient’s GI tract.

View @ Ulcerative Colitis Market Report

Medication for UC can suppress the inflammation of the colon and allow for tissues to heal. Symptoms including diarrhea, bleeding, and abdominal pain can also be reduced and controlled with effective medication. The type of medication needed depends upon patient and how severe the symptoms are.

Aminosalicylates contain 5-aminosalicylic acid (5-ASA) and work in the lining of the gastrointestinal tract to in order to reduce inflammation. This in turn allows damaged tissue to heal. They're usually the first treatment option for mild or moderate UC. These medications can be used as a short-term treatment for flare-ups. They can also be taken long term, usually for the rest of the life, to maintain remission. Aminosalicylates work finest in the colon and are often given orally in the form of delayed release tablets, or rectally as enemas or suppositories.

Ulcerative Colitis (UC), is a chronic inflammatory disease of the colon with a relapsing-remitting pattern that can affect individuals of all ages. The current treatment landscape of UC consists of conventional choices such as aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors, anti-TNF agents [Humira (Adalimumab), Remicade (infliximab), and Simponi (golimumab)], antiadhesion molecules [Entyvio (Vedolizumab)], and, more recently, small molecules directed against the JAK pathways [Xeljanz (Tofacitinib)], and anti IL12/23 [STELARA (Ustekinumab)].

For years, TNF inhibitors remain the first therapeutics class that has significantly altered UC treatment. However, the use of TNF inhibitors is restricted even in TNF responders due to systemic effects, including immunosuppression and cardiotoxicity, which restrict its use, particularly in elderly individuals. Remicade is the first anti-TNF-alpha treatment approved in the United States, back in August 1998.

What are the Ulcerative Colitis key players?

Key players such as Aimmune Therapeutics, AbbVie, Boehringer Ingelheim, Hoffmann-La Roche, Genentech, DBV Technologies, Sanofi/Regeneron, Vedanta Biosciences, Eli Lilly and Company, Arena Pharmaceuticals, Kaleido Biosciences and others are involved in developing therapies for Ulcerative Colitis.

Original Source:- Ulcerative Colitis Market Research